3166-28-7Relevant academic research and scientific papers
Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA)
Matthews, Hayden,Ranson, Marie,Tyndall, Joel D.A.,Kelso, Michael J.
scheme or table, p. 6760 - 6766 (2011/12/05)
A known side-activity of the oral potassium-sparing diuretic drug amiloride is inhibition of the enzyme urokinase-type plasminogen activator (uPA, K i = 7 μM), a promising anticancer target. Several studies have demonstrated significant antitum
Synthesis and biological evaluation of aroylguanidines related to amiloride as inhibitors of the human platelet Na+/H+ exchanger
Laeckmann, Didier,Rogister, Fran?oise,Dejardin, Jean-Victor,Prosperi-Meys, Christelle,Géczy, Joseph,Delarge, Jacques,Masereel, Bernard
, p. 1793 - 1804 (2007/10/03)
Pyridine and benzene bioisosteres of amiloride were synthesized and evaluated for their inhibitory potency against the sodium-hydrogen exchanger (NHE) involved in intracellular pH regulation. The inhibition of NHE was determined by using the platelet swelling assay (PSA) in which the swelling of human platelets was induced by their incubation in an acid buffer (pH 6.7). Additionally, the inhibitory potency of the most active compounds was assessed by measuring the inhibition of the EIPA-sensitive 22Na+ uptake (UIA) by human platelets after intracellular acidosis. The results indicated that several benzene derivatives and compounds bearing an carbonylguanidine moiety in the meta position of the pyridine nitrogen were much more potent than amiloride (PSA:IC50=43.5 μM; UIA:IC50=100.1 μM), but less than EIPA, a pyrazine NHE inhibitor (PSA:IC50=0.08 μM; UIA:IC50=0.5 μM). In both biological assays (2-amino-5-bromo-pyridine-3-carbonyl)guanidine (32) was the most active molecule (PSA:IC50=0.8 μM, UIA:IC50=0.8 μM). Our investigations demonstrated that the replacement of the pyrazine ring of amiloride by a pyridine or a phenyl ring improved the NHE inhibitory potency (phenyl >pyridine >pyrazine).
